Sino Biopharmaceutical Limited (SBP Group, 1177.HK) and PT Tempo Scan Pacific Tbk (Tempo Scan) have jointly announced the formal signing of a joint venture agreement to establish PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI) in Indonesia. According to the agreement, SBP Group will hold a 51% stake in TCBI, and Tempo Scan will hold a 49% stake.

On July 22, the inaugural China Pharma Innovation Conference (CPIC 2026) opened at the Shanghai National Exhibition and Convention Center. The "CPIC 2026 Original New Drug Award" was officially announced at the conference. The first-in-class CDK2/4/6 inhibitor, Culmerciclib capsules (Saitanxin), self-developed by CTTQ, the core enterprise of SBP Group (1177.HK), received the award, showcasing Sino Biopharm's strength in pursuing source innovation to address significant clinical needs. Tse Hsin, Executive Director and Senior Vice President of SBP Group, attended the conference.

On July 1, 2026, on the occasion of the 105th anniversary of the founding of the Communist Party of China, the Hong Kong SAR Government announced the 2026 Honours List, the 29th such list since Hong Kong's return to China. Among the recipients, Ms. Cheng Cheung Ling, one of the founders of Chia Tai Pharmaceutical, founding president of the Hong Kong Chinese Association, President of Chia Tai Pharmaceutical Group, and Vice Chairwoman of the Board of Directors of Sino Biopharmaceutical Limited, was awarded the "Gold Bauhinia Star".

On June 25, E-Healthcare Manager released the "Top 100 Chinese Pharmaceutical Innovation Enterprises" list, with Sino Biopharmaceutical Limited (SBP Group, 1177.HK) once again ranking third.